Intervention: Monoclonal antibodies

COCOPREV

France
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Patel 2

United Kingdom
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Adolescents (12-17 years)
  • Emergency department
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab

Gentile

Italy
|
2023-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Sotrovimab

Drysdale 3

United Kingdom
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Primary care
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Sotrovimab
  • Molnupiravir

Rotundo

Italy
|
2022-2023
  • Adults (18-64 years)
  • Fragile population
  • Immunocompromised host
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Sotrovimab
  • Molnupiravir
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Nguyen

France
|
2021-2022
  • Adults (18-64 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Tixagevimab/Cilgavimab

Pinargote-Celorio

Spain
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Sotrovimab

SOLIDARITY Finland Plus Long-COVID

Finland
|
2022-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Intensive care unit
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Immunomodulator
  • Antineoplastic agent
  • Imatinib
  • Infliximab

NOVELLA

Russian Federation
|
2023-2024
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • AZD3152/Sipavibart

Leppert

Italy Spain Switzerland
|
2022-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Outpatient clinic
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Temelimab

Evans

United Kingdom
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Outpatient clinic
  • Community
  • Non-hospital health centre
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Sotrovimab
  • Molnupiravir

Drysdale

United Kingdom
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Adolescents (12-17 years)
  • Immunocompromised host
  • Outpatient clinic
  • Community
  • Non-hospital health centre
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab